CLINICAL ENDOCRINOLOGY

BY

ALLAN WILLIAM SPENCE

M.A., M.D. (Cantab.), F.R.C.P. (London) Physician, St. Bartholomew's Hospital, London



CASSELL AND COMPANY LIMITED LONDON 1953

CASSELL & CO. LTD

37/38 St. Andrew's Hill, Queen Victoria Street London, E.C.4

and at

210 Queen Street, Melbourne
26/30 Clarence Street, Sydney
Haddon Hall, City Road, Auckland, N.Z.
1068 Broadview Avenue, Toronto 6
122 East 55th Street, New York
Galeria Guemes, Escritorio 518/520 Florida 165, Buenos Aircs
Haroon Chambers, South Napier Road, Karachi
17 Central Avenue P.O. Dharamtala, Calcutta
P.O. Box 275, Cape Town
P.O. Box 1386, Salisbury
15 Graham Road, Ballard Estate, Bombay, 1
Islands Brygge 5, Copenhagen
Avenida 9 de Julho 1138/51, Sao Paulo
P.O. Box 959, Acera, Gold Coast
Calcada Do Carma 55–20, Lisbon

First edition 1953

25 rue Henri Barbusse, Paris 5e

ALL RIGHTS RESERVED

PREFACE

This book is written for the general physician and for those aspiring to become clinical endocrinologists. Stress has therefore been laid on the clinical features of endocrine diseases and diagnostic procedures and treatment have been described in some detail. To remind the reader of the debt we owe to the pioneers of the subject the historical aspects of each disease have been briefly described. As in other branches of medicine, a knowledge of physiology is, in the author's opinion, essential for the proper understanding of disordered function and for rational therapeutics, and therefore a brief account has been given of the actions of the various hormones. The anatomy of the endocrine glands has been purposely omitted because, although it is of advantage to be cognisant of the situation of these organs, this knowledge is acquired in one's preliminary studies and detailed information is more suitably obtained in textbooks of anatomy. author has not been bold enough to include diabetes mellitus. for the reason that it is a separate branch of endocrinology and the province of physicians who devote themselves almost entirely to its study.

During the last two decades enormous strides have been made in our knowledge of endocrinology, largely through the work of the chemists and physiologists. There was a time within the memory of the author when endocrinology was the Cinderella of medicine, but now it encroaches on almost every branch and through the original investigations at the Mayo Clinic it has been shown to play an important part in diseases in which hitherto an endocrine factor had never been conceived. The result has been that almost over-night rheumatologists, ophthalmologists, dermatologists and a host of others have taken up the study of this complex subject. A vast literature has grown up, so that to keep pace with the publications relating even to only one gland is a task of some magnitude. far as possible those authors who made the original observations have been quoted in this book, but, to avoid being cumbersome, a large number of investigators who have contributed to the subject have had to pass unmentioned, their place being taken by those who have written monographs or reviews.

The author expresses his thanks to Messrs. Butterworth & Co., Ltd., for kindly granting him permission to incorporate certain sections of his contribution to their publication "Medical Treatment; Principles and Their Application," edited by Dr. Geoffrey Evans. He also thanks Dr. Oliver Garrod for his suggestions and criticism of the chapter on Diabetes Insipidus and Mr. C. W. S. Taylor, B.Sc., A.R.I.C., of the Ciba Laboratories, Ltd., for obtaining for him certain references in respect of the chemistry of the steroid hormones. The author should record his indebtedness to that valuable book by Sir

PREFACE

Humphry Rolleston, "The Endocrine Organs in Health and Disease," which is a mine of historical information.

The bulk of the illustrations are photographs of the author's own cases and for others he is indebted to Dr. William Evans, Mr. M. A. Falconer, F.R.C.S., Dr. A. Shapiro and Dr. D. A. G. Galton and to his colleagues and erstwhile colleagues at St. Bartholomew's Hospital, namely. Sir Francis Fraser, Sir Thomas Dunhill, Mr. Geoffrey Keynes, F.R.C.S., Dr. C. F. Harris, Mr. Rupert Corbett, F.R.C.S., Mr. John Hosford, F.R.C.S., Mr. C. Naunton Morgan, F.R.C.S., Dr. E. F. Scowen, Dr. A. W. Franklin, Dr. I. G. Williams and Dr. V. C. Medvei. Thanks are due to Messrs. Butterworth & Co., Ltd., for permission to publish Figures 2 and 3, which appear in the author's article on Acromegaly in the British Encyclopædia of Medical Practice, 2nd Edition and Figure 21 from Surgical Progress 1952, to the F. A. Davis Company for Figure 37 from the author's article in Cyclopedia of Medicine, to the Editor of the British Journal of Cancer for permission to publish Figures 42 and 43, to the Editors of the Proceedings of the Royal Society of Medicine for Figures 10 and 25, to the Clarendon Press for Figures 11, 12 and 36, to Messrs. John Wright & Sons for Figure 45, and to the Photographic Department of the Luton and Dunstable Hospital for Plate II. Finally, it is a pleasure to record the author's indebtedness to Mr. N. K. Harrison, A.R.P.S., and his staff of the Photographic Department, St. Bartholomew's Hospital, for their long-continued and helpful co-operation.

A. W. SPENCE

C-c-c-I	Т	Description Control of the Control o		PAGE
SECTION I.		PITUITARY GLAND AND THE HYPOTHALAMUS	•	•
Chapter	I.	The Pituitary Hormones	•	3
		The Growth Hormone The Gonadotrophic Hormones .	•	3 6
		The Conadotrophic Hormone .	•	10
		The Adrenocorticotrophic Hormone	•	10
		The Lactogenic Hormone .		13
		Antihormones		14
		The Posterior and Intermediate Lobes		16
		The Hypothalamus		19
Chapter	II.	Tumours of the Pituitary Gland .		22
Chapter	III.	Acromegaly		33
		Gigantism		47
Chapter	ľV.	Cushing's Syndrome		51
Chapter	V.	Hypopituitarism	•	70
Chapter	VI.	Hypothalamic and Posterior Pituitary S dromes	yn-	88
		Fröhlich's Syndrome		88
		Diabetes Insipidus		92
		Hand-Schüller-Christian Syndrome		100
		Hyperfunction of the Posterior Lobe	•	101
		Laurence-Moon-Biedl Syndrome . Polyostotic Fibrous Dysplasia .	•	102 105
SECTION II.	Тн	E THYROID GLAND		
Chapter	VII.	The Thyroid Hormone		115
Chapter '	VIII.	Simple Goitre		126
Chapter	IX.	Toxic Goitre		140
Chapter	X.	Hypothyroidism		185
		Cretinism		185
		Myxœdema	•	192
		Juvenile Myxædema	•	204
		Mild Hypothyroidism	•	205
•	XI.	Tumours of the Thyroid Gland .	•	207
Chapter	XII.	Thyroiditis	•	210
		Acute Thyroiditis	•	210
		Chronic Thyroiditis	•	211
		Lymphadenoid Goitre	•	213

				PAGE
SECTION III. TH	ie Parathyroid Glands			
Chapter XIII.	The Parathyroid Hormone.			217
Chapter XIV.	Hypoparathyroidism .			221
	Pseudohypoparathyroidism .			228
Chapter XV.	Hyperparathyroidism .	•		230
	Secondary Hyperparathyroidism			230
	Primary Hyperparathyroidism	•		231
	Acute Hyperparathyroidism	٠	•	241
SECTION IV. TH	E ADRENAL GLANDS			
Chapter XVI	. The Adrenal Hormones .		•	245
-	The Medullary Hormones			246
	The Cortical Hormones		•	249
	The Pituitary-Adrenal System			259
	Stress			259
	Diseases of Adaptation .			261
Chapter XVII	. Cortisone and the Adrenocort		phic	
	Hormone in General Medicine	•	•	263
Chapter XVIII	. Addison's Disease .		•	269
Chapter XIX	. Adrenal Hæmorrhage .			291
Chapter XX	. Hyperfunction of the Adrenal Co	rtex		297
	Adrenal Virilism .			298
	Adrenal Feminism .	•	•	309
Chapter XXI	. Tumours of the Adrenal Medulla	•	•	312
	Sympathetic Nerve Cell Tumou	ırs	•	312
	Phæochromocytoma .	•	•	314
SECTION V. THE	MALE ORGANS OF REPRODUCTION			
Chapter XX	II. The Testicular Hormone			325
Chapter XXI	III. Eunuchism			333
Chapter XXI	IV. Hypogonadism			338
•	The Male Climacteric . `			346
Chapter XX				349
<u>-</u>	Impotence			349
	Excessive Libido .			351
Chapter XX	VI. Undescended Testes .		•	352
Chapter XXV	II. Endocrine Tumours of the Test	es	•	361

		PAGE
Chapter XXVIII. Disorders of the Prostate and Seminal Vesicles	of the	363
		363
Benign Hypertrophy of the Pro Carcinoma of the Prostate	istate.	364
Chronic Hæmospermia .	•	366
•	•	500
SECTION VI. THE FEMALE ORGANS OF REPRODUCTION		
Chapter XXIX. The Ovarian Hormones		369
The Sex Hormones in Pregnancy	•	382
Chapter XXX. Ovarian Infantilism		387
Ovarian Agenesis (Turner's Syndr	rome) .	392
Chapter XXXI. Disorders of Menstruation .		398
Amenorrhæa		398
Functional Dysmenorrhæa.		405
Intermenstrual Pain		411
Premenstrual Tension		411
Functional Uterine Hæmorrhag	ge .	413
Chapter XXXII. Disorders of Libido	•	424
Frigidity		424
Excessive Libido	•	425
Chapter XXXIII. Endocrine Tumours of the Ova	ary and	
Endometriosis	•	426
Chapter XXXIV. Disorders of Pregnancy		429
Toxæmias of Pregnancy .	•	429
Threatened and Habitual Abort	tion .	429
Diabetes Mellitus	•	431
Induction of Labour	•	432
Chapter XXXV. The Climacteric	•	434
SECTION VII. THE BREASTS		
Chapter XXXVI. Hormonal Control of the Breast	is .	443
Chapter XXXVII. Disorders of the Breasts .		446
Under-development of the Bre	easts .	446
Hypertrophy of the Breasts.		447
Failure of Lactation.		447
Suppression of Lactation and o	of Breast	
Engorgement	•	449
Persistent Lactation.		450
Fibro-adenosis of the Breast (Chronic	455
Mastitis) .	•	452
Carcinoma of the Breast	•	455
Gynæcomastia	•	459

							PAGE
SECTION VII	I. MISCE	llaneous Di	SORDER	S			
Chapter X	XXVIII.	The Pineal	Body a	ind the T	hymus Gl	and	467
		Physiolog	gy of th	e Pineal	Body		467
		Pineal Tu	imours				467
		Physiolog	gy of th	ne Thymi	is Gland		468
		Patholog	y of the	e Thymu	s Gland		469
		Myasther	nia Gra	ıvis .	•		470
Chapter	XXXIX.	Intersexuali	ity .		•		472
Chapter	XL.	Sexual Prec	ocity	•	•		485
Chapter	XLI.	Dwarfism a	nd Inf	antilism	•		495
Chapter	XLII.	Obesity		•	•		505
Chapter	XLIII.	Sterility and	d Subfe	ertility	•		524
Chapter	XLIV.	Hyperinsuli	inism	•	•	•	536
Chapter	XLV.	Estrogens	and	Androge	ns in N	Ais-	
•		cellane	ous Di	sorders			540
		Acne Vu	lgaris		•		540
		Atrophic		is .			541
		Bone Dis	seases				541
		Buccal	Leuco	plakia	and Bu	ccal	
		Ulcera					543
		Enuresis		•	•	•	544
		Phimosis		•	•		544
		Prematu	rity .	•	•	•	545
APPENDIX.	Prenarati	ons and Me	thods	of Adm	inistration	ı of	
AFFENDIA.		Hormones			•		546
REFERENCES	•		•		•		5 57
INDEX OF A	UTHORS		•		•	•	641
GENERAL IN	DEX			_			653

LIST OF ILLUSTRATIONS


					PAGE
Fig.	1.	Normal sella turcica and enlargement due to phobe adenoma .	a chrom	o-	27
Fig.	2.	Acromegalic hand	•		39
Fig.	3.	Acromegaly			40
Fig.	4.	Gigantism			49
Fig.	5.	Cushing's syndrome with dwarfing .			58
Fig.	6.	Cushing's syndrome before and after treatm	ent		67
Fig.	7.	Purpuric striæ in Cushing's syndrome			67
Fig.	8.	Purpuric striæ in pulmonary tuberculosis			68
Fig.	9.	Adipose gynandrism	•		91
Fig.	10.	Laurence-Moon-Biedl syndrome .	•		103
Fig.	11.	Polyostotic fibrous dysplasia .	•		107
Fig.	12.	Skiagram of polyostotic fibrous dysplasia			109
Fig.	13.	Simple goitre	•		126
Fig.	14.	Lingual goitre	•		136
Fig.	15.	Toxic goitre	•		140
Fig.	16.	Toxic goitre in a child			143
Fig.	17.	A: unilateral upper lid-retraction . B: bilateral exophthalmos	•		152 152
Fig.	18.	Pigmentation and leucoderma in toxic goitr	е		154
Fig.	19.	Exophthalmic ophthalmoplegia .	•		161
Fig.	20.	Localized pretibial myxædema in toxic goit	re		165
Fig.	21.	Chemosis before and after irradiation of the	e orbit		183
Fig.	22.	Sporadic cretinism		•	189
Fig.	23.	Achondroplasia			191
Fig.	24.	Myxœdema	•	•	196
Fig.	25.	The heart in myxædema before and after to	reatment		198
Fig.	26.	Myxœdema before and after treatment	•		204
Fig.	27.	The hand in acute tetany	•		224
Fig.	28.	Pathological appearances of generalized oste	itis fibro	sa	234
Fig.	29.	Renal calculi in hyperparathyroidism	•	•	234

LIST OF ILLUSTRATIONS

		PAGE
Fig. 30.	Radiological appearances of generalized osteitis fibrosa	236
Fig. 31.	The adrenogenital syndrome before and after treatment	303
Fig. 32.	Adrenal tumour demonstrated by perirenal insufflation	307
Fig. 33.	Schematic diagram to illustrate Albright's conception	
	of the pituitary-testis interrelations	332
Fig. 34.	Eunuchism before and after treatment	337
Fig. 35.	Eunuchoidism	342
Fig. 36.	Eunuchoidism before and after treatment	345
Fig. 37.	Bilateral cryptorchidism	359
Fig. 38.	Average excretion rates of various hormones during pregnancy	384
Fig. 39.	Turner's syndrome	394
Fig. 40.	Turner's syndrome	395
Fig. 41.	Failure of development of one breast	446
Fig. 42.	Mammary carcinoma before and after treatment with methyltestosterone	456
Fig. 43.	Pulmonary metastases of mammary carcinoma before and after treatment with testosterone	457
Fig. 44.	Gynæcomastia of puberty	463
Fig. 45.	Myasthenia gravis before and after treatment .	471
Fig. 46.	Female genital intersexuality (female pseudoherma- phroditism)	477
Fig. 47.	Female genital intersexuality (female pseudoherma- phroditism)	479
Fig. 48.	Hypertrophy of clitoris in female genital intersexuality	480
Fig. 49.	Vagina in female genital intersexuality	480
Fig. 50.	Constitutional sexual precocity	489
Fig. 51.	Constitutional sexual precocity	490
Fig. 52.	Genetic dwarfism	499
Fig. 53.	Pituitary infantilism	500
Fig. 54.	Pituitary infantilism	502
Fig. 55.	Pituitary infantilism due to a craniopharyngioma .	502
Fig. 56.	Extreme obesity	511
Fig. 57.	Extreme obesity in a young woman	512
Fig. 58.	Extreme obesity in a child	514
Fig. 59.	Cervical lipomatosis.	517
=	xii	

SECTION I

THE PITUITARY GLAND AND THE HYPOTHALAMUS



CHAPTER I

THE PITUITARY HORMONES¹

THE ANTERIOR LOBE

THE effects of hypophysectomy and the administration of specific extracts of the anterior lobe of the pituitary gland have demonstrated that the anterior lobe controls by means of its secretions the function of nearly all the other endocrine glands. There are at present six different hormones that are known to be elaborated, namely, the growth hormone, the two gonadotrophic hormones (the follicle stimulating hormone and the luteinizing or interstitial cell stimulating hormone), the thyrotrophic hormone, the adrenocorticotrophic The secretion of certain hormone and the lactogenic hormone. hormones of the anterior lobe itself, however, appears to be kept in check by the hormones of those glands which are stimulated by its specific secretions. Evidence for this statement is found in the excessive excretion in the urine of the follicle stimulating gonadotrophin that occurs after castration and in its disappearance from the urine as a result of the administration of suitable doses of œstrogen. Similarly, thyroidectomy causes an increased production of thyrotrophic hormone which is diminished or abolished by the administration of thyroid hormone. There normally exists a delicate hormonal balance between the anterior lobe of the pituitary gland and the peripheral glands, so that excessive pituitary secretion and secondary hyperactivity of the peripheral glands are prevented.

THE GROWTH HORMONE

HISTORICAL NOTE

That the pituitary gland secreted a hormone concerned with growth was long suspected as a result of clinical observations; gigantism was connected with hyperactivity of the gland and dwarfism was observed to be sometimes associated with its destruction. In the experimental field Aschner (1909) demonstrated that removal of the pituitary gland from puppies caused arrest of growth and of development. This work was subsequently confirmed in the rat by Smith (1926) and by many other investigators. The proof of the existence of a growth hormone was supplied by Evans and Long (1921), who reported the experimental

CLINICAL ENDOCRINOLOGY

production of gigantism in rats by daily injections of extract of the anterior lobe of the pituitary gland over a prolonged period. The growth hormone (termed by H. M. Evans "somatotropin") was isolated in pure form by Li and Evans (1944). It is a protein, readily destroyed by pepsin and trypsin, with a molecular weight of 44,250 (Li, Evans and Simpson, 1945).

ACTIONS

Growth. The growth hormone causes gain in body weight through its direct action on the tissues and not through the mediation of other endocrine glands. Li and Evans (1948) injected pure growth hormone into adult female rats six days a week for 435 days and observed that growth continued during the whole period with no sign of lack of responsiveness. The average gain in weight was 289 g., compared with 57 g. in the control animals; the average body length of the experimental rats was 45.5 cm., of the control animals 40.9 cm. The weights of the liver, kidneys, heart, stomach and intestine of the injected rats per 100 g. of body weight remained practically the same as in the control animals.

The site of action of growth hormone in promoting growth of bone appears to be localized mainly in the proliferating zone of the epiphyseal cartilages (Freud, Levie and Kroon, 1939). After hypophysectomy the dimensions of the epiphyseal plate are reduced and a calcium barrier appears between the epiphysis and the diaphysis, preventing longitudinal growth. The administration of growth hormone leads to the rapid disappearance of this "closing membrane" and restores the dimensions of the cartilaginous plate by stimulating firstly chondrogenesis and later osteogenesis (Kibrick, Becks, Marx and Evans, 1941).

The growth promoting action of growth hormone is enhanced by the administration of thyroid hormone. Evans, Simpson and Pencharz (1939) observed that excessive growth produced by anterior pituitary extracts is not dependent on the presence of the thyroid gland, but is greater when the thyroid gland is present; that the promotion of the growth of thyroidectomized or thyroidectomized-hypophysectomized animals in excess of normal secured by anterior pituitary extracts is maximal only if the thyroid hormone is administered at the same time; and that thyroid hormone, which promotes the growth of thyroidectomized animals, does not have this effect when it is administered to thyroidectomized-hypophysectomized animals.

Metabolism. Growth hormone has been shown to cause nitrogen retention, a reduction in the level of the blood amino acids, an increase in the protein content and a decrease in the fat content of the carcass, an increase of the plasma alkaline phosphatase and an increase of the plasma inorganic phosphorus (Li and Evans, 1948). The hormone thus promotes the anabolism of protein. Nitrogen retention leads to

THE PITUITARY GLAND

water retention and the water content of animals treated with growth hormone is significantly higher than in the control animals. This fluid retention accounts for the obese appearance of the animals treated with growth hormone. Young (1945) suggested that depletion of the fat stores was due to increased combustion of fat to supply the necessary energy for the building up of protein into muscle.

Evans, Meyer, Simpson and Reichert (1932) produced a diabetic state in dogs by the daily injection of a preparation of pituitary growth hormone for 8-9 months and the condition persisted for some weeks after the treatment was stopped. Young (1937) induced permanent diabetes in two dogs by the daily injection of anterior pituitary extract; the disorder differed from that caused by pancreatectomy in that the animals were able to survive without the administration of insulin. The islets of Langerhans showed disappearance of the cytoplasmic granules of the beta cells or extensive hyalinization of the cellular tissue (Richardson and Young, 1938). The factor responsible for these changes was known as the diabetogenic hormone. Young (1940), who had observed that diabetogenic preparations of the anterior lobe usually possessed growth promoting activity, suspected that the growth hormone and the diabetogenic principle might be identical, and later pure growth hormone was found to be diabetogenic in the cat and in the dog (Cotes, Reid and Young, 1949; Campbell, Davidson, Snair and Lei, 1950).

STANDARDIZATION

There are three methods for the standardization of growth hormone that may be employed.

- (1) Body growth of normal female rats. The preparation to be assayed is injected intraperitoneally or subcutaneously into groups of at least 10 normal female rats, 5 to 6 months of age and weighing 220 to 280 g., for 20 days (17 injections). A unit is contained in that daily dose which causes a total increase of weight of 40 g. during this period (Evans, Uyei, Bartz and Simpson, 1938).
- (2) Body growth of hypophysectomized female rats. Nine intraperitoneal injections of the preparation are given in 10 days to groups of 10 completely hypophysectomized female rats, 28 to 30 days of age at operation, starting 10 to 14 days after the operation. A unit is the daily dose which causes an average gain in weight of 10 g. (Evans, Uyei, Bartz and Simpson, 1938).
- (3) Tibia of hypophysectomized rats. The preparation is injected intraperitoneally daily for 4 days into hypophysectomized female rats, 26 to 28 days of age at operation, starting 12 to 13 days after the operation. The animal is killed 24 hours after the last injection, the right tibia is split, stained with silver nitrate and sodium thiosulphate and the uncalcified portion of the epiphysis is measured. The initial

CLINICAL ENDOCRINOLOGY

effects of growth hormone consist mainly of chondrogenesis and the resulting increase in the width of the cartilage is, within certain limits of dosage, proportional to the quantity of growth hormone injected (Evans, Simpson, Marx and Kibrick, 1943).

THE GONADOTROPHIC HORMONES

HISTORICAL NOTE

For many years before the demonstration in 1926 that the anterior lobe of the pituitary gland secreted a hormone essential for the normal development and function of the gonads this relationship was strongly suggested by clinical and laboratory observations. Experimentally it had been shown that hypophysectomy caused atrophy of the reproductive system (Crowe, Cushing and Homans, 1910; Aschner, 1912) and that the injection of anterior lobe extracts into normal female rats produced excessive luteinization of the ovaries (Evans and Long, 1922). The work of Smith (1926, 1927), of Zondek and Aschheim (1926) and later of other investigators demonstrated conclusively that the anterior lobe maintained and controlled the activity of the ovaries and testes. The administration of gonadotrophic extracts to immature rats or mice induced precocious sexual maturity, ovulation and the formation of corpora lutea.

Fluhmann (1929) and Zondek (1930) observed that women at the menopause or after castration contained in their blood and urine a gonadotrophic hormone the effect of which was predominantly follicle stimulating. Fevold, Hisaw and Leonard (1931) first separated pituitary gonadotrophic extracts into two fractions—one which caused maturation of the follicles of the ovaries and the other which brought about luteinization after the follicles had been stimulated to activity by the follicle stimulating fraction. These discoveries led to the conception that there were two gonadotrophic hormones—the follicle stimulating hormone and the luteinizing hormone. It was later shown that the follicle stimulating factor stimulated spermatogenesis in the male animal, but had little or no effect on the testicular interstitial tissue (Smith, Engle and Tyndale, 1934). Stimulation of the interstitial tissue was found to be brought about by the luteinizing substance and therefore the term interstitial cell stimulating hormone was applied to this hormone rather than luteinizing hormone because lutein tissue does not occur in the male organism.

The interstitial cell stimulating hormone was isolated in pure form from the anterior lobes of sheep and swine by Li, Simpson and Evans (1940) and by Shedlovsky and his colleagues (1940) independently. The hormone behaves as a homogeneous protein. The follicle stimulating hormone has not yet been isolated, but almost pure preparations